Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

HIV/AIDS-specific quality of life and adherence to antiretroviral therapy over time.

Holmes WC, Bilker WB, Wang H, Chapman J, Gross R.

J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):323-7.

PMID:
17846560
2.

An adherence typology: coping, quality of life, and physical symptoms of people living with HIV/AIDS and their adherence to antiretroviral treatment.

Bader A, Kremer H, Erlich-Trungenberger I, Rojas R, Lohmann M, Deobald O, Lochmann R, Altmeyer P, Brockmeyer N.

Med Sci Monit. 2006 Dec;12(12):CR493-500.

PMID:
17136004
3.

Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence.

Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu AW, Friedland G; Terry Beirn Community Programs for Clinical Research on AIDS..

AIDS Care. 2005 Jan;17(1):10-22.

PMID:
15832830
4.

Quality of life and its correlates in HIV/AIDS male outpatients receiving highly active antiretroviral therapy in Taiwan.

Yen CF, Tsai JJ, Lu PL, Chen YH, Chen TC, Chen PP, Chen TP.

Psychiatry Clin Neurosci. 2004 Oct;58(5):501-6.

5.
6.

[Clinical status, adherence to HAART and quality of life in HIV-infected patients receiving antiretroviral treatment].

Ruiz-Pérez I, Olry de Labry-Lima A, López-Ruz MA, del Arco-Jiménez A, Rodríguez-Baño J, Causse-Prados M, Pasquau-Liaño J, Martín-Rico P, Prada-Pardal JL, de la Torre-Lima J, López-Gómez M, Marcos M, Muñoz N, Morales D, Muñoz I.

Enferm Infecc Microbiol Clin. 2005 Dec;23(10):581-5. Spanish.

PMID:
16324546
7.

Social support and medication adherence in HIV disease in KwaZulu-Natal, South Africa.

Ncama BP, McInerney PA, Bhengu BR, Corless IB, Wantland DJ, Nicholas PK, McGibbon CA, Davis SM.

Int J Nurs Stud. 2008 Dec;45(12):1757-63. doi: 10.1016/j.ijnurstu.2008.06.006.

PMID:
18653188
8.

Quality of life in patients with human immunodeficiency virus infection: impact of social support, coping style and hopelessness.

Swindells S, Mohr J, Justis JC, Berman S, Squier C, Wagener MM, Singh N.

Int J STD AIDS. 1999 Jun;10(6):383-91.

PMID:
10414881
9.

Comparison of HIV/AIDS-specific quality of life change in Zimbabwean patients at western medicine versus traditional African medicine care sites.

Taylor TN, Dolezal C, Tross S, Holmes WC.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):552-6. doi: 10.1097/QAI.0b013e31818d5be0.

PMID:
18989225
10.

Effects of nurse-delivered home visits combined with telephone calls on medication adherence and quality of life in HIV-infected heroin users in Hunan of China.

Wang H, Zhou J, Huang L, Li X, Fennie KP, Williams AB.

J Clin Nurs. 2010 Feb;19(3-4):380-8. doi: 10.1111/j.1365-2702.2009.03048.x.

PMID:
20500277
11.

A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials.

Clayson DJ, Wild DJ, Quarterman P, Duprat-Lomon I, Kubin M, Coons SJ.

Pharmacoeconomics. 2006;24(8):751-65. Review.

PMID:
16898846
12.

Impacts of HIV infection and HAART use on quality of life.

Liu C, Ostrow D, Detels R, Hu Z, Johnson L, Kingsley L, Jacobson LP.

Qual Life Res. 2006 Aug;15(6):941-9.

PMID:
16900275
13.

Personality, quality of life and HAART adherence among men and women living with HIV/AIDS.

Penedo FJ, Gonzalez JS, Dahn JR, Antoni M, Malow R, Costa P, Schneiderman N.

J Psychosom Res. 2003 Mar;54(3):271-8.

PMID:
12614837
14.

Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients.

Horberg MA, Silverberg MJ, Hurley LB, Towner WJ, Klein DB, Bersoff-Matcha S, Weinberg WG, Antoniskis D, Mogyoros M, Dodge WT, Dobrinich R, Quesenberry CP, Kovach DA.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):384-90.

PMID:
18091609
15.

The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice.

Villes V, Spire B, Lewden C, Perronne C, Besnier JM, Garré M, Chêne G, Leport C, Carrieri MP, Le Moings V; ANRS CO-8 APROCO-COPILOTE Study Group..

Antivir Ther. 2007;12(7):1067-74.

PMID:
18018765
16.

Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study.

Parienti JJ, Massari V, Reliquet V, Chaillot F, Le Moal G, Arvieux C, Vabret A, Verdon R; POSOVIR Study Group..

AIDS. 2007 Oct 18;21(16):2217-22.

PMID:
18090049
17.

Baseline predictors of three types of antiretroviral therapy (ART) adherence: A 2-year follow-up.

Nilsson Schönnesson L, Diamond PM, Ross MW, Williams M, Bratt G.

AIDS Care. 2006 May;18(4):407-14.

PMID:
16809121
18.

A programme of symptom management for improving quality of life and drug adherence in AIDS/HIV patients.

Chiou PY, Kuo BI, Lee MB, Chen YM, Chuang P, Lin LC.

J Adv Nurs. 2006 Jul;55(2):169-79.

PMID:
16866809
19.

Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda.

Bajunirwe F, Tisch DJ, King CH, Arts EJ, Debanne SM, Sethi AK.

AIDS Care. 2009 Mar;21(3):271-9. doi: 10.1080/09540120802241863.

PMID:
19280404
20.

Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya.

Karcher H, Omondi A, Odera J, Kunz A, Harms G.

Trop Med Int Health. 2007 May;12(5):687-94.

Items per page

Supplemental Content

Support Center